Avadomide

DB14857InvestigationalSmall molecule

Avadomide is under investigation in clinical trial NCT02031419 (Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma).

Formula / weight: C₁₄H₁₄N₄O₃ · 286.291 g/mol (avg)
Also known as: 3-(5-Amino-2-methyl-4-oxo-4H-quinazolin-3-yl)piperidine-2,6-dione
Code names: CC-122

Resolves to

Compound

UNII28DZS29F59CAS1015474-32-4ChEMBLCHEMBL3989934

Structure

InChIKeyRSNPAKAFCAAMBH-UHFFFAOYSA-NSMILESCC1=NC2=C(C(N)=CC=C2)C(=O)N1C1CCC(=O)NC1=O

Targets

Q96SW2CRBN

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

15Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Avadomide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account